La Jolla, CA – August 4, 2015 – SGI-DNA, a Synthetic Genomics, Inc. (SGI) company, was recently recognized by Frost & Sullivan for its groundbreaking innovation in genomic technologies for the BioXp™ 3200 System, an instrument with the capacity to simultaneously build 32 unique, double-stranded DNA fragments to study gene function, pathways, and whole genomes. Frost & Sullivan, leveraging over 50 years of experience in partnering with Global 1000 companies, evaluated the BioXp™ System’s new product attributes and customer impact, and awarded SGI-DNA its 2015 North American Synthetic Biology New Product Innovation Award at a ceremony July 16, 2015, in Boston, Mass.
La Jolla, CA & Cambridge, MA – June 11, 2015 – Synthetic Genomics Inc. (SGI), a synthetic biology company advancing and innovating genomic science and technologies for transformative products and solutions, and Gen9 Inc., a pioneer in synthetic biology and leader in the development of scalable technologies for synthesizing and assembling DNA, today announced a strategic licensing agreement to leverage their respective strengths in synthetic biology technology development and commercialization.
Menlo Park, CA – April 28, 2015 – The International Gene Synthesis Consortium (IGSC), an association of the world’s leading gene synthesis companies, today announced that it has established itself as a not-for-profit U.S. corporation. The move is intended to make it easier for the organization to welcome new members, especially small companies, not-for-profits and academic institutions, so that they may leverage the biosecurity expertise of the IGSC.
La Jolla, CA – April 02, 2015 – SGI-DNA Inc. today announced the launch of the BioXp™ 3200 System Early Access Program giving researchers priority access to this one of a kind, personal DNA work station which delivers high quality synthetic DNA fragments. The BioXp™ Instrument has the capacity to simultaneously build 32 unique double-stranded DNA fragments.
La Jolla, CA – January 21, 2015 – SGI-DNA announces the launch of the Gibson Assembly® Ultra Kit which allows researchers to perform complex, large, and multiple fragment assemblies in a simple, two-step reaction.
La Jolla, CA — November 20, 2014 — SGI-DNA announces the launch of the Gibson Assembly® HiFi 1 Step Kit which allows researchers to assemble multiple, large DNA fragments in a simple one hour, one-step reaction.
La Jolla, CA — October 27, 2014 — Synthetic Genomics, Inc. (SGI), a synthetic biology company commercializing genomic technologies to revolutionize several industries, today announced the appointment of Oliver Fetzer, Ph.D., MBA as the company’s new Chief Executive Officer (CEO). In his role as CEO Fetzer will also be a member of SGI’s Board of Directors. Founding CEO, J. Craig Venter, Ph.D., will remain actively involved in SGI as Executive Chairman and Co-Chief Scientist with Co-Founder, Hamilton Smith, M.D.
Kearny, NJ & La Jolla, CA – June 20, 2014 – Avoca, Inc., a division of Pharmachem Laboratories, Inc., has formed a supply agreement with Synthetic Genomics, Inc. (SGI), a privately held company developing and commercializing genomic driven solutions and products in a variety of industries, to extract and commercialize natural astaxanthin from a strain of algae developed by SGI.
La Jolla, CA & Decatur, IL — May 19, 2014 — Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Archer Daniels Midland Company (NYSE: ADM) announced today that the two companies have entered into a long-term agreement to commercialize Omega-3 Docosahexaenoic Acid (DHA) from algae. As part of the agreement, Omega-3 DHA will be produced and marketed throughout the world by ADM’s Foods & Wellness and Animal Nutrition groups. Financial details of the deal were not disclosed.
La Jolla, CA & Silver Spring, MD — May 6, 2014 — Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Lung Biotechnology Inc., a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), today announced they have entered into a multi-year research and development agreement to develop humanized pig organs using synthetic genomic advances. The collaboration will focus upon developing organs for human patients in need of transplantation, with an initial focus on lung diseases.